Table 2 Factors in relation to early neurologic deterioration after acute intracerebral hemorrhage

Number

33

91

Age (years)

59.3 ± 11.5

62.3 ± 12.4

0.224

Gender (male/female)

16/17

53/38

0.334

Body mass index (kg/m²)

26.1 ± 3.1

25.5 ± 3.5

0.407

Hypertension

19 (57.6%)

55 (60.4%)

0.774

Diabetes mellitus

11 (33.3%)

17 (18.7%)

0.085

Hyperlipidemia

9 (27.3%)

29 (31.9%)

0.624

Coronary heart disease

2 (6.1%)

7 (7.7%)

1.000

Cigarette smoking

16 (48.5%)

28(30.8%)

0.068

Alcohol drinking

14 (42.4%)

28 (30.8%)

0.226

Pretreatment of statins

9 (27.3%)

22 (24.2%)

0.725

Pretreatment of anticoagulation drugs

1 (3.3%)

4 (4.4%)

1.000

Pretreatment of antiplatelet drugs

6 (18.2%)

10 (11.0%)

0.363

Pretreatment of antihypertensive drugs

19 (57.6%)

48 (52.7%)

0.634

Pretreatment of hypoglycemic drugs or insulin

9 (27.3%)

12 (13.2%)

0.065

Admission time (h)

10.1 (7.6–15.0)

9.2 (5.8–12.6)

0.292

Blood-collection time (h)

11.8 (8.8–17.5)

10.9 (6.9–14.0)

0.341

Systolic arterial pressure (mmHg)

141.2 ± 21.2

148.3 ± 23.5

0.126

Diastolic arterial pressure (mmHg)

85.0 ± 8.9

88.7 ± 11.4

0.093

Hemorrhage locations (lobar / deep)

7/26

25/66

0.481

Extension of hematoma into intraventricular cavity

12 (36.4%)

20 (22.0%)

0.106

Extension of hematoma into subarachnoidal space

5 (15.2%)

6 (6.6%)

0.160

NIHSS scores

11 (10–16)

7 (4–9)

< 0.001

Hematoma volume (ml)

26 (16–32)

13 (10–19)

< 0.001

Blood leucocyte count (×10⁹/l)

9.6 (8.1–11.5)

7.8 (6.4–9.7)

0.026

Blood glucose levels (mmol/l)

13.8 (10.2–21.5)

10.7 (9.0-12.6)

0.002

Serum MANF levels > 52.5 ng/ml

21 (63.3%)

21 (23.1%)

< 0.001